English (UK)
中文版Huahai Investment Co., Ltd 
Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.
Mr. Hanson Lo
Director, BDHumanwell Healthcare
Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.
Mr. Zhehang DENG
Executive AssistantRoby Chen
投资部经理
HUYA BIOSCIENCE INTERNATIONAL 
Yung-Chih Wang
Senior Vice President, Corporate Development China金丽 杨
科学联络经理晓煊 胡
科学联络经理超骏 龚
科学联络经理Renfei WANG
Scientific liaison manager
I-Mab Biopharma
We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders
Weiming Tang
Global Business Head and Executive VPFernando Salles
SVP, Head of US and EU Business DevelopmentIASO Bio
Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.
Bob Zhao
BD DirectorIaso Biotherapeuticals, Co Ltd
A clinical stage bio pharmaceutical company focus on immunotherapy of tumor and autoimmune diseases.
Dongxiao Feng
Senior Director of Business DevelopmentICBC Asia Investment
Private Equity investment platform of ICBC.
ICBC Asia investment is a wholly-owned holding equity investment platform of industrial and commercial bank of China (ICBC). Managing over 44 billion yuan unlist equity investment. Direct investment over 172 projects, indirect investment in over 2400 companies.
Mr Kaijun Huang
Investment Director
Responsive Web Design powered by 